Episode 391: ASCO GU 2025 - KIM-1 Data From CheckMate 214

By The Uromigos - Last Updated: February 19, 2025

Dr. Vincent Xu of Dana-Farber Cancer Institute discusses this emerging RCC biomarker and data from the Checkmate 214 trial.

Post Tags:Uromigos-Kidney Cancer
Advertisement

Related Podcasts

Episode 392: ASCO GU 2025 - HIF Inhibition With Casdatifan in Refractory RCC
Uromigos-Kidney Cancer
Episode 390: ASCO GU 2025 - Pembro-Based Doublets in Refractory RCC and COSMIC-313 OS Update
Uromigos-Kidney Cancer
Episode 388: ASCO GU 2025 - FGFR3 Inhibition With LOXO-435 in Urothelial Cancer
Uromigos-Bladder Cancer
Episode 389: ASCO GU 2025 - NIAGARA Pathologic CR Updates and Outcomes
Uromigos-Bladder Cancer
Episode 387: ASCO GU 2025 - Neoadjuvant Disitamab Vedotin + Toripalimab in HER2+ MIBC: Updated Efficacy and Safety Results
Uromigos-Bladder Cancer
Advertisement
Advertisement

  • 630 Madison Ave.

    Manalapan, NJ 07726

    • About

    About Us

    Contributors and Partners

    Editorial Policy

    Advertising

    Connect

    eNewsletters

    Calendar

    Contact Us

    Contribute

    Our Network

    MashupMD

    Cancer Nursing Today

    Urban Health Today

    Blood Cancers Today

    DocWire News

    © 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.

    Terms of Use | Privacy Policy |